reports
- Jonathan Moreland
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Fina...
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% compared t...
Treace Highlights New Product Innovations and Updated Positive Clinica...
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™, MTA3D™, and SpeedMTP® clinical studies at the American College of Foot and Ankle Surgeons (“ACFAS”) Annu...
Humacyte Announces Presentation of Symvess® Long-Term Safety and Effic...
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting - Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society - - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvage, low rates of infection, and no unprovoked structural failures - - Long-term durability results showed no dilatation nor narrowing of Symvess diameter out to 36 months - DURHAM, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform...
Norwegian Cruise Line Holdings Enters Into Agreement With Fincantieri ...
Norwegian Cruise Line Holdings Enters Into Agreement With Fincantieri for Three New Cruise Ships Agreements include one ship for each brand, Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises, strengthening long-term fleet growth through 2037 MIAMI, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH), a leading global cruise company operating Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises, today announced that it has entered into an agreement with Fincantieri for the design and construction of three new cruise ships...
Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Res...
Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026 PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results be...
Norwegian Cruise Line Holdings Appoints John W. Chidsey as President ...
Norwegian Cruise Line Holdings Appoints John W. Chidsey as President and Chief Executive Officer Proven Consumer Brand Executive to Drive Next Phase of Growth and Execution MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH), a leading global cruise company operating Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises, today announced that its Board of Directors has appointed John W. Chidsey, a director of NCLH, as President and Chief Executive Officer, effective immediately. Mr. Chidsey succeeds Harry Sommer, who is stepping dow...
Norwegian Cruise Line Holdings to Hold Conference Call on Fourth Quart...
Norwegian Cruise Line Holdings to Hold Conference Call on Fourth Quarter and Full Year 2025 Financial Results MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., “Norwegian Cruise Line Holdings” or the “Company”) announced today it will report fourth quarter and full year 2025 financial results on Monday, March 2, 2026 at 6:30 a.m. Eastern Time with a conference call and webcast to discuss results at 8:00 a.m. Eastern Time. The conference call will be webcast via the Company’s Investor Relations website, . A repla...
Humacyte Announces New U.S. Department of Defense Funding for Procurem...
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently adopted FY 2026 U.S. Department of Defense (DoD) Appropriations Act includes dedicated funding to support the evaluation and incorporation of biologic vascular repair technologies for the warfighters suffering from traumatic vascular injuries...
Leggett & Platt Announces 4Q and Full Year 2025 Earnings Call
Leggett & Platt Announces 4Q and Full Year 2025 Earnings Call Carthage, MO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Leggett & Platt (NYSE:LEG), a diversified manufacturer of engineered products serving several major markets, will release fourth quarter and full year earnings results on Wednesday, February 11, 2026 after the market closes, and hold its quarterly conference call to discuss fourth quarter and full year results, annual guidance, market conditions, company initiatives, and related matters on Thursday, February 12, 2026, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). This call...
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2...
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results. Highlights: Preliminary revenue of $62.1 million to $62.5 million in the fourth quarter of 2025, an approximate 9% decrease at the midpoint over the same period ...
Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ ...
Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first case utilizing its Lapiplasty® Lightning™ technology. Lightning technology expands upon Treace’s market-leading Lapiplasty® System with advanced new instrumentation designed to reduce surgical steps, pr...
Humacyte Announces Hospital Charge Data Showing High Expense of Preven...
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications - Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such as amputation and conduit infection increased initial hospital charges by approximately $493,000 and $590,000 per patient respectively – - Humacyte’s Symvess® has consistently demonstrated low rates of infection and high rates of limb salvage – DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage bio...
Humacyte Announces Planned Marketing Authorization Application for Sym...
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle East, is also planned - DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it plans to file a Marketing Authorization Applica...
- Wedbush Research
VIRC VIRCO MANUFACTURING CORP.
TPH TRI POINTE HOMES INC.
TOL TOLL BROTHERS INC.
RWT REDWOOD TRUST INC.
MTH MERITAGE HOMES CORPORATION
LGIH LGI HOMES INC.
LEN LENNAR CORPORATION CLASS A
SKY SKYLINE CHAMPION CORPORATION
WD WALKER & DUNLOP INC.
DHI D.R. HORTON INC.
BLDR BUILDERS FIRSTSOURCE INC.
TMHC TAYLOR MORRISON HOME CORPORATION
MHO M/I HOMES INC.
CVCO CAVCO INDUSTRIES INC.
ZG ZILLOW GROUP INC. CLASS A
HOV HOVNANIAN ENTERPRISES INC. CLASS A
UFPI UFP INDUSTRIES INC.
Treace to Present at 44th Annual J.P. Morgan Healthcare Conference
Treace to Present at 44th Annual J.P. Morgan Healthcare Conference PONTE VEDRA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that John T. Treace, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, beginning at approximately 7:30 am PT. A live webcast and replay of the fireside chat will be available on the ...
Humacyte Announces Publication of Long-Term Safety and Efficacy Result...
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair - Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - - Results represent first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit - DURHAM, N.C., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platfor...
Treace Medical Secures Up to $175 Million in Debt Financing
Treace Medical Secures Up to $175 Million in Debt Financing New 5-Year Agreement Provides Continued Financial Strength & Flexibility PONTE VEDRA, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it has entered into a new five year $175 million senior secured loan arrangement with credit funds managed by SLR Capital Partners, consisting of $60 million in term loans funded at close,...
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue ...
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, providing up to $77.5 million in principal amount of new financing. The credit agreement, which has a term of four years, includes an initial tranche of $40 millio...
Norwegian Cruise Line Holdings Appoints Marc Kazlauskas as President o...
Norwegian Cruise Line Holdings Appoints Marc Kazlauskas as President of Norwegian Cruise Line Kazlauskas brings decades of experience leading global travel companies and delivering guest-centric innovation MIAMI, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) today named travel industry veteran Marc Kazlauskas as President of Norwegian Cruise Line (Norwegian), effective Jan. 19, 2026. He joins the company with more than 30 years of senior leadership experience across sales, operations, and innovation in the global travel industry. Kazlauskas most rec...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.